IL1B and metabolic dysfunction-associated steatohepatitis: Based on these results, therapeutic targeting of NLRP3 as a treatment of patients with NASH has also been considered, either directly targeting the NLRP3 complex with pharmacologic agents or downstream products including IL-1b and IL-18.